Current therapeutic strategies for multiple myeloma
Yoshihiro Torimoto1, Motohiro Shindo, Katsuya Ikuta
1Oncology Center, Asahikawa Medical University Hospital, 2-1, Midorigaoka-Higashi, Asahikawa, Hokkaido, 078-8510, Japan, tori@asahikawa-med.ac.jp.
Novel molecular targeting agents have transformed multiple myeloma treatment, improving survival rates. While effective, challenges remain in managing relapsed or refractory disease, necessitating further research into optimal therapies.
Area of Science:
- Hematology
- Oncology
- Pharmacology
Background:
- Multiple myeloma is an incurable hematologic malignancy.
- Conventional chemotherapies have limited efficacy.
- Novel molecular targeting agents represent a paradigm shift in treatment.
Purpose of the Study:
- To review the impact of novel agents on multiple myeloma therapy.
- To discuss current treatment strategies for newly diagnosed and relapsed/refractory patients.
- To highlight the need for further research in optimizing treatment regimens.
Main Methods:
- Review of current literature on novel molecular targeting agents in multiple myeloma.
- Analysis of therapeutic strategies for different patient populations (newly diagnosed, transplant-eligible/ineligible, relapsed/refractory).
- Discussion of emerging agents and future research directions.
Main Results:
- Novel agents (thalidomide, bortezomib, lenalidomide) significantly improve response rates, progression-free survival, and overall survival.
- Standard induction and salvage therapies incorporating novel agents are established.
- A new generation of agents (pomalidomide, carfilzomib, panobinostat) shows promise for relapsed/refractory disease.
Conclusions:
- Novel agents have dramatically improved multiple myeloma outcomes.
- Treatment selection requires consideration of patient status and disease stage.
- Further clinical trials are essential to determine optimal drug combinations and patient selection for novel therapies.
More Related Videos
09:41An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
Published on: July 15, 2015
07:24Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos
Published on: December 13, 2018
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:57Targeted Cancer Therapies
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:49Cancer Therapies
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:27Tumor Immunotherapy